eli lilly news - Search News

Eli Lilly to join lawsuit over GLP-1 shortage

Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,

Hosted on MSN · 2d

Eli Lilly asks to join FDA in opposing lawsuit from pharmacies

CNBC's Becky Quick reports on news from Eli Lilly. US surgeon general urges cancer warnings for alcoholic drinks 14 Trader Joe's Items That Have Gained a Cult Following for a Good Reason

Becker's Hospital Review · 2d

Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .

The Hill · 3d

Pharma giant seeks to join lawsuit against FDA over weight loss drugs

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

2don MSN

Eli Lilly & Co. stock rises Friday, still underperforms market

Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...

Pharmaceutical Technology7h

LY-4052031 by Eli Lilly and Co for Ovarian Cancer: Likelihood of Approval

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

4don MSN

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

10d

Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Yahoo Finance3d

Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Pharmaceutical Technology8h

MORF-057 by Eli Lilly and Co for Ulcerative Colitis: Likelihood of Approval

MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on ...

Is Eli Lilly Stock a Buy?

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

emjreviews.com2d

Could Eli Lilly take the crown in the obesity market?

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

FiercePharma2d

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly to join lawsuit over GLP-1 shortage

Related topics